trial · primary record
Giredestrant
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 316 |
| Primary completion | 2029-05-30 |
| Primary endpoint | Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) |
| Registry ID | NCT04802759 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:08.864Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04802759
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Giredestrant · compound